Embecta Corp (EMBC) fair value: what the stock is really worth
As of Oct 12, 2026: fair value of Embecta Corp $17.97, price $5.99, upside +200.0%, quality 75 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
55‑month range $2.89 – $48.11 · fair‑value band $11.63 – $28.70 · the $5.99 price screens below the $17.97 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Embecta in your weekly email
Every Wednesday you see whether Embecta is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Show more
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Stock analysis
Embecta Corp (EMBC) currently trades at $5.99, while our model-based Fair Value estimate is $17.97, implying the stock looks roughly 66.7% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $37.04 per share, and 19 of the 21 models we run sit above the $5.99 price.
Bear case: the Dividend Discount group reads lowest at $5.17, and 2 of the 21 models stay below the price. Evidence for this calculation is low.
Scenario range: $11.63 (bear) to $28.70 (bull), the price of $5.99 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 75/100 (high quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Embecta Corp reported revenue of $1.1B in FY2025 versus $1.2B in FY2021, a compound −1.9%/yr. Reported net income was $95.4M in FY2025, compounding −30.7%/yr from FY2021.
Key figures
Market cap $350M · P/E ratio 4.1 · P/S ratio 0.36 · EPS (TTM) $1.47 · Dividend yield 7.7% · Net margin 8.8% · Return on assets (EBIT) 32.0% · Operating margin 23.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).
What moves the price
The share trades about 58% below its 52-week high and 107% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −36% fair-value upside, at 200%, EMBC screens cheaper than that median.
Fair Value models
Bear $11.63Fair Value $17.97Bull $28.70
Price $5.99 · Upside +200.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then ($1.01 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−3.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.1%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.4%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−11.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−19.4%
Dividend (yield on the price)7.7%
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.45% → 16%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 186 stocks
Beats the industry median on 10/11 measures
Overall it ranks above its industry peers.
Valuation
Quality Score75 · Top 25%
Fair Value upside+200.0% · Top 25%
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets12.2% · Top 25%
Net margin (TTM)8.6% · Above median
Operating margin (TTM)23.7% · Top 25%
Growth and dividend
Revenue growth−8.1% · Bottom 25%
Dividend yield (TTM)7.7% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)4.1× · Cheapest 25%
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM)0.34× · Cheapest 25%
P/FCF1.9× · Cheapest 25%
EV/EBITDA5.4× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)100· sector 17
FUTURE (revenue growth)0· sector 37
PAST (return on equity)0· sector 28
HEALTH (low debt)0· sector 96
DIVIDEND (yield)100· sector 32
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Embecta Corp Fair Value". https://www.fairvalue-calculator.com/stock/EMBC
Frequently asked questions
Is Embecta Corp (EMBC) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of $17.97 versus a price of $5.99, about +200% upside (undervalued).
What is the fair value of EMBC?
Our model-based fair value for Embecta Corp is $17.97 (as of Oct 2, 2026), built from audited fundamentals. The current price: $5.99.
What is the quality score of EMBC?
Embecta Corp has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Embecta Corp (EMBC)?
Our model-based price target is the fair value of $17.97 (as of Oct 2, 2026) from 21 valuation models. Cautious scenario $11.63, optimistic scenario $28.70. It is a calculation from audited fundamentals, not an analyst target.
What is the Embecta Corp stock forecast for 2026?
Our models put fair value at $17.97, about +200% upside versus a price of $5.99 (undervalued). Cautious scenario $11.63, optimistic scenario $28.70. The calculation is refreshed regularly with new filings.
What is the revenue of Embecta Corp (EMBC)?
Embecta Corp reported trailing-twelve-month revenue of about $1.0B (latest available figure, as of Oct 2, 2026).
Does Embecta Corp pay a dividend?
Embecta Corp currently shows a dividend yield of about 7.68% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Embecta Corp (EMBC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Embecta Corp it is $17.97 per share (as of Oct 2, 2026), against a price of $5.99. It is the blended result of 21 valuation models (cash flow, earnings, asset, dividend).
Is Embecta Corp stock overvalued or undervalued in 2026?
As of Oct 2, 2026, EMBC trades below its calculated fair value: price $5.99, fair value $17.97, a gap of about +200% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EMBC?
No. The price is what the market pays today ($5.99); the fair value is what the company's own numbers justify ($17.97). For Embecta Corp the two are $11.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Embecta Corp worth?
The market values Embecta Corp at about $350M (market capitalisation, as of Oct 2, 2026). Per share that is $5.99; our models calculate a fair value of $17.97 per share.
What do the bullish and bearish scenarios say about EMBC?
Our models span a range for Embecta Corp: cautious scenario $11.63, base $17.97, optimistic $28.70 per share (as of Oct 2, 2026, price $5.99). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of EMBC?
Embecta Corp trades at a price-to-earnings ratio of 4.1 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $17.97 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 2.0 (reported for FY2025: 3.7). Other multiples: P/S 0.3, EV/EBITDA 5.4.
How solid is the balance sheet of Embecta Corp (EMBC)?
Balance-sheet figures for Embecta Corp (as of Oct 2, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is EMBC from its 52-week high?
Embecta Corp trades at $5.99, about 58% below its 52-week high of $14.20 and 107% above the low of $2.89 (as of Oct 12, 2026). Distance from the high says nothing about value: that is what the fair value of $17.97 is for.
Which stocks are comparable to Embecta Corp?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Embecta Corp stock attractive at the current price?
The data as of Oct 2, 2026: price $5.99, calculated fair value $17.97 (+200%), Quality Score 75/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EMBC calculated?
We run Embecta Corp through 21 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $17.97, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.8 % above its aggregate fair value. Embecta Corp currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Embecta Corp (EMBC)?
The closing price on Oct 12, 2026 was $5.99. Our model-based fair value is $17.97, about +200% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Embecta Corp right now?
The rarer combination: high quality (75/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case ($11.63). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($11.63 to $28.70) leaves room in how you read the outcome.
Key figures of Embecta Corp
How large is the market capitalisation of Embecta Corp (EMBC)?
The market capitalisation of Embecta Corp is $350M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Embecta Corp (EMBC)?
The price-to-sales ratio of Embecta Corp is 0.36 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Embecta Corp (EMBC)?
Earnings per share at Embecta Corp are $1.47 (price ÷ EPS = P/E 4.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Embecta Corp (EMBC)?
The dividend yield of Embecta Corp is 7.7% (payout 17.2%, on adjusted earnings, reported 31.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Embecta Corp (EMBC)?
The net margin of Embecta Corp is 8.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Embecta Corp (EMBC)?
On an EBIT basis the return on assets of Embecta Corp is 32.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Embecta Corp (EMBC)?
The operating margin of Embecta Corp is 23.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Embecta Corp (EMBC)?
Revenue at Embecta Corp is growing −8.1% versus a year earlier (3y avg −1.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Embecta Corp (EMBC)?
Earnings per share at Embecta Corp are growing −53.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Embecta Corp (EMBC) generate?
The free cash flow of Embecta Corp is $182M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Embecta Corp (EMBC) carry?
The net debt of Embecta Corp is $1.2B (fiscal year 2025, ≈ 6.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Embecta Corp in the live analysis
One click puts Embecta Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 2, 2026